SeaGen’s Josephson Jumps to Zymeworks to Lead Clinical Research

Neil Josephson is joining Zymeworks (NYSE: [[ticker:ZYME]]) to become vice president of clinical research. Josephson comes to the Vancouver, BC-based drug developer from Seattle Genetics (NASDAQ: [[ticker:SGEN]]), where he was vice president of clinical development. In other moves, Zymeworks appointed Mark Hollywood to serve as senior vice president, technical and manufacturing operations, and Bruce Hart to the position of vice president, regulatory affairs. The company also promoted David Poon to vice president, business development and alliance management. Zymeworks is developing antibody drugs to treat cancer and other diseases.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.